Key result
The combination of trabectedin and radiation therapy was well-tolerated and effective in treating a cardiac metastasis from leiomyosarcoma, resulting in substantial dimensional reduction and survival of over 18 months.
Why the study?
Metastatic spread to the heart carries a poor prognosis with no known effective treatment, and cardiac metastases of soft-tissue sarcomas are very rare.
Does the combination of radiation therapy and trabectedin reduce tumor size and improve survival in a patient with cardiac metastasis from leiomyosarcoma?
Case Report (n=1)
No
Does the combination of radiation therapy and trabectedin reduce tumor size and improve survival in a patient with cardiac metastasis from leiomyosarcoma?
The combination of radiation therapy and trabectedin may be a feasible, well-tolerated, and effective treatment for rare cardiac metastases from soft-tissue sarcomas.
Answers are grounded in this paper and cite their sources.
May support trabectedin-radiation in rare cardiac leiomyosarcoma metastases; leaves open efficacy in prospective cohorts.
Leiomyosarcoma (LMS) is one of the most frequent subtypes of soft-tissue sarcomas (STSs). Metastatic spread to the heart in cancer patients carries a poor prognosis and there is no known effective treatment. Cardiac metastases of STSs are very rare. Here we present the case of a 55-year-old patient who underwent surgical resection of a retroperitoneal leiomyosarcoma and then developed widespread metastatic disease, treated with a combination of local treatment and systemic therapy. Three years after surgical resection she presented with a cardiac intraventricular mass, which was treated with radiation therapy, while receiving systemic therapy with trabectedin. Such combination therapy was well-tolerated and effective, allowing a substantial dimensional reduction which is perduring to date, 18 months after diagnosis of cardiac metastasis. Available literature and data point to the feasibility and good tolerability of radiation therapy and trabectedin in metastatic sarcoma, yet this is the first report on the effectiveness of the combination for the treatment of cardiac disease. The extended survival since a metastatic relapse (more than 3 years) is likely the result of integrated systemic and loco-regional treatment, which should be always discussed within the framework of a multiprofessional and multidisciplinary setting.
No takes yet. Share an insight, caveat, or question.
Tortorelli et al. (2022) conducted a case report in Cardiac metastasis from leiomyosarcoma (n=1). Trabectedin and radiation therapy was evaluated on Tumor response and survival. The combination of trabectedin and radiation therapy was well-tolerated and effective in treating a cardiac metastasis from leiomyosarcoma, resulting in substantial dimensional reduction and survival of over 18 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: